We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

51 hedge funds and large institutions have $162M invested in Dianthus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 5

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

6% more funds holding

Funds holding: 48 → 51 (+3)

0.13% more ownership

Funds ownership: 2.44% → 2.57% (+0.13%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

11% less capital invested

Capital invested by funds: $182M → $162M (-$19.9M)

Holders
51
Holders Change
+3
Holders Change %
+6.25%
% of All Funds
1.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
12
Reduced
5
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CC
Casdin Capital
New York
+$2.83M
2
OM
Opaleye Management
Massachusetts
+$2.3M
3
Fidelity International
Fidelity International
Bermuda
+$1.71M
4
BlackRock
BlackRock
New York
+$942K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$914K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$1.51M
2
Citadel Advisors
Citadel Advisors
Florida
-$1.17M
3
Goldman Sachs
Goldman Sachs
New York
-$1.02M
4
Alkeon Capital Management
Alkeon Capital Management
New York
-$918K
5
Norges Bank
Norges Bank
Norway
-$893K
Name Holding Trade Value Shares
Change 		Change in
Stake
Norges Bank
26
Norges Bank
Norway
$86K -$893K -4,241 -90%
California State Teachers Retirement System (CalSTRS)
27
California State Teachers Retirement System (CalSTRS)
California
$73K +$80.2K +381 New
GHCM
28
Glen Harbor Capital Management
California
$56K – – –
MCIM
29
Meadow Creek Investment Management
Georgia
$46K – – –
EP
30
Elkfork Partners
Oregon
$37K – – –
AIG
31
American International Group
New York
$32K +$35.1K +167 New
TAM
32
Tyers Asset Management
Texas
$27K – – –
MSA
33
Marino Stram & Associates
Massachusetts
$20K +$21.5K +102 New
UBS Group
34
UBS Group
Switzerland
$19K +$6.1K +29 +41%
Barclays
35
Barclays
United Kingdom
$18K +$20K +95 New
Citigroup
36
Citigroup
New York
$14K +$14.9K +71 New
SO
37
STRS Ohio
Ohio
$14K +$15.8K +75 New
JP Morgan Chase
38
JP Morgan Chase
New York
$11K +$12.2K +58 New
SWM
39
SeaCrest Wealth Management
New York
$10K -$2.74K -13 -21%
Bank of America
40
Bank of America
North Carolina
$10K +$10.9K +52 New
RCM
41
Riverhead Capital Management
Delaware
$9K – – –
Legal & General Group
42
Legal & General Group
United Kingdom
$8K +$9.05K +43 New
Wells Fargo
43
Wells Fargo
California
$7K +$7.58K +36 New
TRCT
44
Tower Research Capital (TRC)
New York
$6K +$6.74K +32 New
TDC
45
Thompson Davis & Co
Virginia
$4K – – –
VFA
46
Valeo Financial Advisors
Indiana
$4K – – –
AIP
47
Ameritas Investment Partners
Nebraska
$4K +$4.42K +21 New
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$3K +$2.95K +14 New
AG
49
Advisor Group
Arizona
$2K +$2.53K +12 New
CHP
50
Cable Hill Partners
Oregon
$1K +$1.26K +6 New
1
2
3

DNTH Hedge Fund Activity: Q3 2018 in Review

51 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2018, worth a combined $162M — down 11% from $182M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new DNTH positions and 16 closed out — a net gain of 3 holders — while 12 added to existing stakes and 5 trimmed.

The largest buyer was Casdin Capital, adding an estimated $2.83M. The largest seller was Millennium Management, exiting entirely with an estimated $1.51M sold.

  • 51 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2018, up from 48 in Q2 2018.
  • Funds reported $162M of Dianthus Therapeutics stock for Q3 2018, down 11% quarter-over-quarter.
  • 19 funds opened new Dianthus Therapeutics positions in Q3 2018 and 16 closed out, a net change of +3 holders.
  • The largest Dianthus Therapeutics buyer in Q3 2018 was Casdin Capital, an estimated $2.83M added.
  • The largest Dianthus Therapeutics seller in Q3 2018 was Millennium Management, an estimated $1.51M sold.

Based on aggregated 13F filings for Q3 2018.